Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086 | EVP, Chief Experience Officer | June 08, 2020 | June 09, 2020 |
| Hyatt Hotels CorpH · Entity 3345 | See Remarks | March 22, 2017 | March 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXION PHARMACEUTICALS, INC.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,423 |
Reported balance
After 2020-06-08 transaction · row 1
1 source rowRow 1 · 2020-06-08 · Tax withholding · Disposed 2,561 · Balance 41,423 F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.
Hyatt Hotels Corp
Report date March 22, 2017 · Filed March 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,748 |
Reported balance
After 2017-03-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-22 · Grant · Acquired 4,748 · Balance 4,748 F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at settlement, one share of Class A Common Stock. F2: The RSUs issued pursuant to the Third Amended and Restated Hyatt Hotels Corporation Long-Term Incentive Plan ("LTIP") vest and become payable in four equal annual installments beginning on March 16, 2018. The RSUs will be settled in Class A Common Stock upon vesting, subject to earlier settlement upon death or disability or a change of control of the Issuer. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $52.65 · Expires 2027-03-22 | Direct | 15,290 |
Reported balance
After 2017-03-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-22 · Grant · Acquired 15,290 · Balance 15,290 F3: The stock appreciation rights issued pursuant to the LTIP vest in four equal annual installments beginning on March 16, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at settlement, one share of Class A Common Stock.
F2: The RSUs issued pursuant to the Third Amended and Restated Hyatt Hotels Corporation Long-Term Incentive Plan ("LTIP") vest and become payable in four equal annual installments beginning on March 16, 2018. The RSUs will be settled in Class A Common Stock upon vesting, subject to earlier settlement upon death or disability or a change of control of the Issuer.
F3: The stock appreciation rights issued pursuant to the LTIP vest in four equal annual installments beginning on March 16, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 08, 2020 Filed Jun 9, 2020 17:01 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock | 2,561 | $114.61 | $293,516.21 |
DisclosureSEC source: 0000899866-20-000064 · wf-form4_159173647156532.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP, Chief Experience Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,423 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 18:21 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock | 1,308 | $90.54 | $118,426.32 |
DisclosureSEC source: 0000899866-20-000021 · wf-form4_158327768133879.xml · nonDerivative · entry 2 LAW ANNE-MARIE · CIK 0001409438 · EVP, Chief Experience Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,984 F2 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.48 - $92.39. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 18:21 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-20-000021 · wf-form4_158327768133879.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP, Chief Experience Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,292 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 18:37 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock | 2,563 | $118.61 | $303,997.43 |
DisclosureSEC source: 0000899866-19-000075 · wf-form4_156029261096736.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP, Chief Experience Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,092 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 17:40 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | Tax withholdingCommon Stock | 634 | $132.93 | $84,277.62 |
DisclosureSEC source: 0000899866-19-000040 · wf-form4_155173924299136.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP, Chief Experience Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,816 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.90- $135.06. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 20:12 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock | 8,839 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-19-000044 · wf-form4_155183463058092.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP, Chief Experience Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,655 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 16:51 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | SaleCommon Stock | 1,862 | $118.53 | $220,702.86 |
DisclosureSEC source: 0000899866-18-000103 · wf-form4_152883669230270.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP and CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,450 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document |
| February 28, 2018 Filed Mar 2, 2018 17:02 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock | 8,344 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-18-000063 · wf-form4_152002812048759.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP and CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,312 F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 18:34 UTC | ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086 | GrantCommon Stock, par value $.0001 per share | 22,968 | $0.00 | $0.00 |
DisclosureSEC source: 0000899866-17-000134 · wf-form4_149704767410642.xml · nonDerivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · EVP and CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · shares: Award of Restricted Stock Units under the 2017 Incentive Plan. 25% vest on each anniversary of the grant date. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 20:29 UTC | Hyatt Hotels Corp H · Entity 3345 | GrantStock Appreciation Rights · Derivative | 15,290 | $0.00 Strike: $52.65 | $0.00 |
DisclosureSEC source: 0001468174-17-000040 · wf-form4_149038736561768.xml · derivative · entry 2 LAW ANNE-MARIE · CIK 0001409438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,290 Underlying: Class A Common Stock · 15,290 shares Expires 2027-03-22 F3 · derivative.exercise_date: The stock appreciation rights issued pursuant to the LTIP vest in four equal annual installments beginning on March 16, 2018. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 20:29 UTC | Hyatt Hotels Corp H · Entity 3345 | GrantRestricted Stock Units · Derivative | 4,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001468174-17-000040 · wf-form4_149038736561768.xml · derivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,748 Underlying: Class A Common Stock · 4,748 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at settlement, one share of Class A Common Stock. F2 · derivative.exercise_date: The RSUs issued pursuant to the Third Amended and Restated Hyatt Hotels Corporation Long-Term Incentive Plan ("LTIP") vest and become payable in four equal annual installments beginning on March 16, 2018. The RSUs will be settled in Class A Common Stock upon vesting, subject to earlier settlement upon death or disability or a change of control of the Issuer. F2 · derivative.expiration_date: The RSUs issued pursuant to the Third Amended and Restated Hyatt Hotels Corporation Long-Term Incentive Plan ("LTIP") vest and become payable in four equal annual installments beginning on March 16, 2018. The RSUs will be settled in Class A Common Stock upon vesting, subject to earlier settlement upon death or disability or a change of control of the Issuer. Read SEC document |
| December 08, 2016 Filed Dec 12, 2016 21:21 UTC | Hyatt Hotels Corp H · Entity 3345 | GrantRestricted Stock Units · Derivative | 17,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001468174-16-000260 · wf-form4_148157767497570.xml · derivative · entry 1 LAW ANNE-MARIE · CIK 0001409438 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,667 Underlying: Class A Common Stock · 17,667 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at settlement, one share of Class A Common Stock. F2 · derivative.exercise_date: The RSUs issued pursuant to the Third Amended and Restated Hyatt Hotels Corporation Long-Term Incentive Plan vest and become payable in four equal annual installments beginning on December 12, 2017. The RSUs will be settled in shares of Class A Common Stock upon vesting, subject to earlier settlement upon death or disability or a change of control of the Issuer. F2 · derivative.expiration_date: The RSUs issued pursuant to the Third Amended and Restated Hyatt Hotels Corporation Long-Term Incentive Plan vest and become payable in four equal annual installments beginning on December 12, 2017. The RSUs will be settled in shares of Class A Common Stock upon vesting, subject to earlier settlement upon death or disability or a change of control of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.